MoonLake Immunotherapeutics (MLTX) Q2 2024 Earnings
MLTX·Reported August 7, 2024·Before market open
Diluted EPS came in at $-0.39, missed the $-0.28 consensus by $0.11.
Diluted EPS
$-0.39missed by $0.11
Consensus: $-0.28
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about MoonLake Immunotherapeutics's Q2 2024 earnings report.
MoonLake Immunotherapeutics (MLTX) reported Q2 2024 earnings on August 7, 2024 before market open.
MoonLake Immunotherapeutics reported diluted EPS of $-0.39 for Q2 2024.
EPS missed the consensus estimate of $-0.28 by $0.11.
You can read the 10-Q periodic report (0001821586-24-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.